Actively Recruiting
Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis
Led by University of Erlangen-Nürnberg Medical School · Updated on 2025-09-26
12
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.
CONDITIONS
Official Title
Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Uncontrolled treatment resistant hypertension despite taking 3 different antihypertensive medication classes, confirmed by 24-hour ambulatory blood pressure (office BP 202140/90 mmHg and/or ambulatory BP 202130/80 mmHg)
- End-stage renal disease on chronic hemodialysis
- Stable hemodialysis routine for at least 3 months as decided by the treating physician
- Adherence to a stable drug regimen without changes for at least 4 weeks
- Age 18 years or older, including both male and female patients
You will not qualify if you...
- Episodes of sustained low blood pressure that could interfere with safe renal denervation as judged by the physician
- Significant renal artery abnormalities or narrowing that prevent safe catheter placement
- Prior renal denervation procedure
- Solitary kidney (anatomic or functional) or kidney transplantation
- Severe artery disease or calcification affecting reliable blood pressure measurement
- Endocrine hypertension except due to obstructive sleep apnea
- Heart attack, unstable angina, or stroke within 3 months before screening
- Recent acute systemic or kidney disease requiring increased immunosuppressive drugs within 3 months
- Pregnancy, nursing, or intention to become pregnant
- Participation in another interventional research study
- Any condition that may prevent safe or compliant participation as decided by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and Hypertension
Erlangen, Bavaria, Germany, 91054
Actively Recruiting
Research Team
A
Agnes Bosch, MD
CONTACT
R
Roland E. Schmieder, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here